Price History

Hover for the daily close. The dotted line marks the period open.

Compare PLRZ with… →

PLRZ Key Statistics

As of Sep 4, 2026

Trading

Open: $12.40
Previous Close: $12.56
Day's Range: 11.00–12.72
52-Week Range: 2.88–18.20
Volume: 141.30K

Valuation

Market Cap: $26.66M
P/E Ratio: unprofitable
EPS (ttm): −4.90

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$3.34M
Profit margin: 0.00%
Shares Outstanding: 2.37M
1-Year Return: +75.08%

Dividend and dates

Avg Volume: 61.29K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PLRZ Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+40.00%−99.74%+32.39%

2024*20252026*

Year	Return
2026 (partial year)	+32.39%
2025	−99.74%
2024 (partial year)	+40.00%

As of September 4, 2026.

PLRZ Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$3.34M	—
2024	$0.00	−$1.55M	—
2023	$0.00	−$600.00K	—
2022	$0.00	−$779.00K	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$5.79M	−$3.34M	—
2024	$0.00	—	−$1.30M	−$1.55M	—
2023	$0.00	—	−$635.00K	−$600.00K	—
2022	$0.00	—	−$895.00K	−$779.00K	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PLRZ Valuation vs Biotechnology Median

Median of 656 stocks

Metric	PLRZ	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Polyrizon Ltd. (PLRZ) at $26.66M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 2 employees.

PLRZ last closed at $11.24 on September 4, 2026. That is −$1.32 (−10.51%) against the previous close. Over the past 52 weeks the price has ranged from $2.88 to $18.20. The latest close sits 290.28% above that 52-week low.

Financial Health

In fiscal 2025, Polyrizon Ltd. reported revenue of $0.00. The same year closed with a net loss of $3.34M. Profit margin runs at 0%. Trailing earnings per share are −4.9.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Daily returns over the trailing 1 year annualize to a volatility of 204.79%. Over the trailing twelve months the price has returned +75.08%. The stored price history starts on October 29, 2024, and the total return since then is −99.52%.

Growth & Income

No dividend is on file for PLRZ.

The record holds one complete calendar year, 2025, which returned −99.74%. So far in 2026 the price is +32.39%.

Peer Comparison

Polyrizon Ltd. (PLRZ) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Polyrizon Ltd.	PLRZ	$26.66M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Polyrizon Ltd. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Polyrizon Ltd.

Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.

Visit website →

Polyrizon Ltd. (PLRZ) Stock Analysis